Coronavirus / Biotech Stock News Bites: Moderna (Nasdaq: $MRNA) Announces Supply Agreement With U.S. Government For Initial 100 Million Doses Of Mrna Vaccine Against COVID-19 (Mrna-1273)

(MENAFN- Investor Ideas) Moderna (Nasdaq: $MRNA) Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

CAMBRIDGE, Mass - August 12, 2020 (Investorideas Newswire) Coronavirus / Biotechnology (COVID-19) Stock News Bites - Moderna, Inc., (Nasdaq: MRNA ) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government's goal of securing early access to safe and effective COVID-19 vaccines for the American people.

Today's award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of mRNA-1273 including incentive payments for timely delivery of the product. With the previous award of up to $955 million from BARDA for the development of mRNA-1273 to licensure, today's announcement brings the U.S. government commitments for early access to mRNA-1273 to up to $2.48 billion. Under the terms of the agreement, the U.S. government, as a part of Operation Warp Speed, will also have the option to purchase up to an additional 400 million doses of mRNA-1273 from Moderna. The U.S. government has announced that consistent with its commitment to free access to COVID-19 vaccines, Americans will receive mRNA-1273 at no cost for the vaccine itself. As is customary with government-purchased vaccines, healthcare professionals could charge for the cost of administering the vaccine.

"We appreciate the confidence of the U.S. government in our mRNA vaccine platform and the continued support," said Stéphane Bancel, Moderna's Chief Executive Officer. "We are advancing the clinical development of mRNA-1273 with the ongoing Phase 3 study being conducted in collaboration with NIAID and BARDA. In parallel, we are scaling up our manufacturing capability with our strategic partners, Lonza, Catalent and Rovi, to address this global health emergency with a safe and effective vaccine."

"For Operation Warp Speed, we are assembling a broad portfolio of vaccines to increase the odds that we will have at least one safe, effective vaccine as soon as the end of this year," said HHS Secretary Alex Azar. "With this latest investment, we will have supported the vaccine candidate developed by Moderna in partnership with the NIH all the way from early development through clinical trials and now manufacturing, with the potential to bring millions of safe and effective doses to the American people."

Over the past nine years, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of mRNA-based vaccines. The investments in this proprietary platform have enabled Moderna to expeditiously create, manufacture and clinically develop mRNA-1273 to potentially address the current COVID-19 pandemic. A summary of the company's work to date on COVID-19 can be foundhere.

The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), supported the research and development of mRNA-1273 with $955 million in federal funding under Contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the company for conducting the program described in the BARDA contract. The U.S. government is providing up to $1.525 billion in funding for the supply of mRNA-1273 under U.S. Department of Defense Contract No. W911QY-20-C-0100.

Read the company's full news and disclaimer here:

Visit Investorideas biotech and coronavirus stocks directory

About Investorideas - News that Inspires Big Investing Ideas Investorideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles,podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns:Crypto Corner,Play by Play sports and stock news column,Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change,Exploring Mining theAI Eye.

Stock Bites is a branded product of Investorideas Disclaimer/Disclosure: Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. This stock bites news release publication is available as a paid for service on InvestorideasNews-Upload/

More disclaimer info:Learn more about publishing your news release and our other news services on the Investorideas newswireNews-Upload/ and tickertagstocknews

Global investors must adhere to regulations of each country. Please read Investorideas privacy policy:

Follow us on Twitter

Follow us on Facebook

Follow us on YouTube

Download ourMobile App for iPhone and Android

Get free investor news alerts

Join our Investor Clubmembership/

Contact Investorideas

800 665 0411

BiotechIndustryStocks - investing ideas in biotechnology stocks, medical technology and life sciencesLike Biotech Stocks? View ourBiotech Stocks Directory Get News Alerts on Biotech Stocks

MENAFN30102026000142011025ID1111891938